The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.

Biochemical markers of bone metabolism are strongly associated with skeletal complications in metastatic bone disease. The bisphosphonate clodronate reduces skeletal morbidity by inhibiting bone resorption. This study investigated the use of bone markers to assess the efficacy of oral clodronate across a range of clinically relevant doses.

Current management of molar pregnancy.

Molar pregnancy remains an uncommon and still not fully understood disorder. The clinical presentation has changed over recent decades. In developed countries complete moles are now usually diagnosed early (on clinical and/or ultrasound scan criteria) so that the more severe clinical presentations are much less commonly seen.